Impact of hepatitis C virus coinfection on immune restoration during successful antiretroviral therapy in chronic human immunodeficiency virus type 1 disease

  • M. Santin
  • M. Mestre
  • E. Shaw
  • M. J. Barbera
  • A. Casanova
  • J. Niubo
  • F. Bolao
  • D. Podzamczer
  • F. Gudiol
Article

DOI: 10.1007/s10096-007-0384-3

Cite this article as:
Santin, M., Mestre, M., Shaw, E. et al. Eur J Clin Microbiol Infect Dis (2008) 27: 65. doi:10.1007/s10096-007-0384-3

Abstract

The effect of coinfection with hepatitis C virus (HCV) on immune restoration in 39 human immunodeficiency virus (HIV)-infected patients during treatment with combined antiretroviral therapy (cART) was prospectively evaluated. After 48 weeks of treatment, HCV-coinfected patients had lower increases in CD4% (P = .05), total CD4+ (P = .01), and naïve CD4+ (P = .06) T cells than did single-infected subjects. Higher baseline naïve CD4+ T-cell levels were associated with better CD4+ (P = .05) and naïve CD4+ (P < .001) T-cell recovery. After a 4-year follow up, the differences disappeared (median CD4+ increase: 291 and 306 cells for HCV-positive and HCV-negative patients, respectively, P = .9). No significant differences were seen in memory CD4+ T cells (P = .30), and CD8+ cells expressing CD38 (P = .10) and CD28 (P = .73). These results suggest that, independently of other factors, infection with HCV blunts early CD4+ T-cell recovery in HIV-infected patients treated with combined antiretroviral therapy (cART). However, as good control of viral replication is maintained, satisfactory long-term immune restoration can nonetheless be achieved.

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • M. Santin
    • 1
  • M. Mestre
    • 2
  • E. Shaw
    • 1
  • M. J. Barbera
    • 1
  • A. Casanova
    • 3
  • J. Niubo
    • 3
  • F. Bolao
    • 4
  • D. Podzamczer
    • 1
  • F. Gudiol
    • 1
  1. 1.Department of Infectious DiseasesIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  2. 2.Department of ImmunologyIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  3. 3.Department of MicrobiologyIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain
  4. 4.Department of Internal MedicineIDIBELL, Hospital Universitari de Bellvitge, University of BarcelonaBarcelonaSpain

Personalised recommendations